

BIOTECHGAZINE

生物科技誌

SEPTEMBER 2023

BIOHK2023

香港國際生物科技論壇暨展覽

SEPTEMBER 九月13^{WED} - 16^{SAT}

HONG KONG CONVENTION AND EXHIBITION CENTRE

香港會議展覽中心

BOOTH NO. 3E-A10, 3E-A8, 3E-B7, 3E-B9

BIOHK2023 PLATINUM SPONSOR



ZEIN BIOTECHNOLOGY CO.,LTD.

**WITH MAH AS
THE CORE,
FOCUSING ON
THE FULL
LIFECYCLE
SERVICE
OF DRUGS**

Zein Biotechnology Co., Ltd., founded in 2001, is a national high-tech enterprise engaged in the construction of the full-life cycle management service system of pharmaceuticals, with the capability of compliance management and key technology services for the whole process of drug development, manufacturing, transaction promotion and post-marketing research. We have been approved to establish "Chongqing Chiral Drug Engineering Technology Research Center," "Chongqing New Drug Design Engineering Technology Research Center," and "Chongqing Postdoctoral Research Workstation." At present, the industrial achievements include 33 new drug certificates, 51 production approvals, 11 foreign invention patents (including 2 in the United States, 2 in Europe, 1 in Japan, 2 in South Korea, and 1 in India), and 36 domestic invention patents.



Address: Zhibo Center Podium, No. 38 Yingbin Avenue, Jiulongpo District, Chongqing
Website: www.zeinbio.com

Business docking: Luo Liping 13636361651;

Wang Zhanghong 15730333828

BIOHK2023

香港國際生物科技論壇暨展覽

DISCOVER THE LIMITLESS
POTENTIAL OF HONG KONG'S
BIOTECH ECOSYSTEM

CONFERENCE

会议

DAY ONE

第一天

Wednesday, September 13

星期三，九月十三号

Order of advertisements will be different on the printed version

GSK

Ahead Together

We unite science, technology
and talent to get ahead of
disease together.

PROGRAM DAY 1

WEDNESDAY SEP 13

LAST UPDATED: SEPTEMBER 1 2023

08:30	EVENT REGISTRATION			
	BIOHK AUDITORIUM			
09:00 - 09:30	OPENING CEREMONY			
09:30 - 09:50	KEYNOTE SESSION : MR. CY LEUNG 梁振英 (VICE CHAIRMAN, CPPCC)			
09:50 - 12:40	KEYNOTE SESSION: PROF. BRUCE BEUTLER (NOBEL LAUREATE, CO-FOUNDER OF LONGEVITY X)			
	KEYNOTE SESSION: MR. GEORGE HARA (GROUP CHAIRMAN AND CEO, DEFTA PARTNERS)			
	KEYNOTE SESSION: PROF. JISHENG HAN 韩济生 (ACADEMICIAN, THE CHINESE ACADEMY OF SCIENCES)			
	KEYNOTE SESSION: PROF. YI RAO 饶毅 (PRESIDENT, CAPITAL MEDICAL UNIVERSITY)			
	KEYNOTE SESSION: MR. PETER NOBEL (CHAIRMAN, NOBEL SUSTAINABILITY TRUST)			
	KEYNOTE SESSION: SIR JONATHAN SYMONDS (CHAIR, GSK PLC)			
	BIOHK AUDITORIUM	INNOVATION GALLERIA	TECHNOLOGY HALL	LOCI SQUARE
12:40 - 13:30	<p>SPONSOR: HK LONGEVITY MEDICAL CENTER</p> <p>HEALTHY AGING AND LONGEVITY FORUM</p> <p>Chair: Dr. Christine Huang (HK Longevity Medical Center)</p> <p>Opening: Mr. Amir Lati (CG Israel)</p> <p>Aging biology Dr. Alexey Moskalev (Komi Scientific Center, Russian Academy of Science) Prof. Xin Wang (Chinese University of Hong Kong)</p>	<p>SPONSOR: SCMP</p> <p>THRIVE IN THE BIOTECH MARKET: INVESTING IN LIFE SCIENCE IN HK</p> <p>Moderator: Ms. Elizabeth Cheung (SCMP)</p> <p>Panelists</p> <p>Sir Jonathan Symonds (GSK)</p> <p>Mr. Conrad Tsang (Strategic Year Holdings)</p> <p>Mr. Aaron Finley (Deloitte)</p> <p>Mr. Frank Yang (BOCG)</p>	<p>ETHICS IN THE BIOTECH INDUSTRY</p> <p>Panelists</p> <p>Prof. Yi Rao (Capital Medical University)</p> <p>Prof. Dong Dong (Chinese University of Hong Kong)</p> <p>Ms. Monin Ung (Mung Legal)</p>	<p>SPONSOR: SHANGHAI HEALTHCARE CAPITAL</p> <p>HONG KONG'S TECHNOLOGY INNOVATION TRANSFORMATION</p> <p>Moderator: Mr. Qiushan Guo (Shanghai Healthcare Capital)</p> <p>Mr. Min Zuo (Shanghai Healthcare Capital)</p> <p>Dr. Pengcheng Zhu (ATLTL)</p> <p>Prof. Yuk Ming Lo (Chinese University of Hong Kong)</p> <p>Prof. Yuk Lam Lo (HKBMIA)</p>
13:30 - 14:00	BREAK			
14:00 - 15:30	<p>Prof. Zhongjun Zhou (The University of Hong Kong) Dr. Dajun Chai (Fujian Medical University) Mr. Mike Crichton (GSK)</p> <p>Longevity Investment Panel Mr. Thian Chew (Polar Ventures) Mr. Phil Newman (Longevity Technology) Dr. Hank Wuh (Longevity X) Mr. Sergey Jakimov (LongeVC)</p> <p>Reproductive Aging Prof. Jaron Rabinovici (Sheba Medical Center) Dr. Arthur Yang Zhang (Westlake Medical Sci. Ltd.) Prof. Xiangjun Chen (Shanghai Medical College, Fudan University)</p> <p>Aging medicine Dr. Zhenglong Gu (Greater Bay Area Institute of Precision Medicine) Prof. Hidekazu Yamada (Japanese Society of Anti-Aging Medicine) Dr. Yoko Masuda (Japanese Society of Stem Cell Supernatant for Clinical Medicine) Dr. Mark Tang (Good Health Capital) Dr. Juliane Hitzel (CellFull)</p>	<p>POLICY FOUNDATIONS FOR A LIFE SCIENCE ECOSYSTEM IN HK AND GBA</p> <p>Chair: Dr. Joe Fang (One Country Two System Research Institute)</p> <p>Moderator: Dr. Hon Yuen-shan Wong (Chief Executive's Policy Unit)</p> <p>Dr. Sabrina Chan (HKAPI) Prof. Yuk Lam Lo (HKBMIA) Mr. Vincent Ma (Hong Kong-Shenzhen Innovation & Technology Park) Mr. Arthur Tsang (Our Hong Kong Foundation) Mr. Raymond Yip (Nansha New Area) Dr. Guoliang Yu (BayHelix Group)</p>	<p>SPONSOR: SIRNAOMICS</p> <p>RNA MEDICINE: THERAPEUTICS, VACCINES AND BEYOND</p> <p>Dr. Xiaochang Dai (Sirnaomics) Dr. Patrick Lu (Sirnaomics) Dr. Francois Lebel (Sirnaomics) Dr. Dong Shen (RNAimmune) Dr. Edward Wang (Sirnaomics)</p> <p>Coffee Break</p> <p>RNA Investment Panel Dr. Min Wu (Therona) Dr. Da Liu (CR-CP Life Science Fund) Prof. Nancy Man (The University of Hong Kong) Mr. Christopher Kennedy (EDIRNA)</p> <p>Dr. Yuling Li (Innoforce Pharmaceuticals Co., Ltd.) Mr. Michael Zhang (Guangzhou Ribo Biotechnology) Dr. Richard Welch (Sirnaomics)</p>	<p>REPROGRAMMING FOR REGENERATIVE MEDICINE</p> <p>Chair: Prof. Kathryn Cheah (School of Biomedical Science, HKU)</p> <p>Prof. Ting Xie (Hong Kong University of Science and Technology)</p> <p>Prof. Pengtao Liu (The University of Hong Kong)</p> <p>Prof. Gong Chen (Jinan University, NeuExcell Therapeutics)</p> <p>Dr. Hongmei Li (Beijing University of Chinese Medicine)</p>
16:00 - 17:00		<p>HKEX LISTING</p> <p>Keynote: Prof. Shusong Ba (HKEX)</p> <p>Moderator: Ms. Winnie Han (HKEX)</p> <p>Ms. Lynne Wu (LongevityX) Ms. Mengyang Yang (CICC) Mr. Andrew Ng (VMS Group) Dr. Chang Liu (ASK Health)</p>		<p>SPONSOR: BEIJING ITAI TECHNOLOGY</p> <p>SPECIAL EVENT (BY INVITATION ONLY)</p> <p>ASIAN LIFE SCIENCES AND HEALTHCARE INDUSTRY FINANCIAL FORUM</p>
17:00 - 17:30				
17:30 - 18:00				

ONEZONE PARTNERING

KEYNOTE ADDRESS

Wednesday, September 13 | 09:00 AM - 12:40 PM (GMT+8)

08:45 - 09:30	OPENING CEREMONY
09:30 - 09:50	KEYNOTE SESSION : MR. CY LEUNG 梁振英 , VICE CHAIRMAN, CPPCC
09:50 - 10:20	KEYNOTE SESSION: MR. GEORGE HARA , GROUP CHAIRMAN AND CEO, DEFTA PARTNERS Smart Cells
10:20 - 10:50	KEYNOTE SESSION: PROF. YI RAO 饶毅 , PRESIDENT, CAPITAL MEDICAL UNIVERSITY 中国生物医药产业的起飞
10:50 - 11:10	KEYNOTE SESSION: PROF. JISHENG HAN 韩济生 , ACADEMICIAN OF THE CHINESE ACADEMY OF SCIENCES Application of Acupuncture-related Techniques in Assisted Reproductive Medicine
11:10 - 11:40	KEYNOTE SESSION: MR. PETER NOBEL , CHAIRMAN, NOBEL SUSTAINABILITY TRUST 科技与全球可持续发展, Technology and Global Sustainable Development
11:40 - 12:10	KEYNOTE SESSION: SIR JONATHAN SYMONDS , CHAIR, GSK PLC Building a Data-led Science Eco-system to Support the Health Needs of Today
12:10 - 12:40	KEYNOTE SESSION: PROF. BRUCE BEUTLER , NOBEL LAUREATE, CO-FOUNDER OF LONGEVITY X Automated Meiotic Mapping for the Discovery of Protective Mutations for Disease Resistance to Cancer and the Fragility of Aging
13:30 - 14:00	Lunch Break

LAST UPDATED: SEPTEMBER 1 2023

BIOHK2023 DIAMOND SPONSOR




盈信泰資本介紹

网站: <https://www.ausviccapital.com/en/>

盈信泰資本成立於2018年，由擁有眾多股權投資背景的專業人士發起建立的前沿科技投資管理機構。創始人陳平先生擁有豐富的高科技領域風險投資及企業管理經驗，並創造了驕人的業績。我們投資全球優秀項目，重點投資領域包括：生物科技、人工智能與大數據、雲計算及數字經濟。同時，盈信泰資本與世界知名家族基金和頂尖大學有著深度合作關係

What science can do

We push the boundaries of science to deliver life changing medicines



HK-5958_25/6/2023



Bruce Beutler

Nobel Prize Laureate

Winner of the 2011 Nobel Prize in Physiology or Medicine

Bruce Beutler, MD, discovered an important family of receptors that allow mammals to sense infections when they occur, triggering a powerful inflammatory response. For this work he received the 2011 Nobel Prize in Physiology or Medicine.

Beutler received his undergraduate degree from the University of California at San Diego in 1976, and his MD degree from the University of Chicago in 1981. After two years of residency at the University of Texas Southwestern Medical Center, he became a postdoctoral fellow and then an Assistant Professor at the Rockefeller University (1983-1986), where he isolated mouse tumor necrosis factor (TNF), and was the first to recognize TNF as a key executor of the inflammatory response. Returning to Dallas in 1986 as an HHMI investigator, he designed recombinant inhibitors of TNF that are widely used in the treatment of rheumatoid arthritis and other inflammatory diseases. He also used TNF as a biological endpoint in order to identify the receptor for bacterial lipopolysaccharide (LPS). This he achieved by positionally cloning the Lps mutation of mice, known to prevent all biological responses to LPS, including TNF production. He thus concluded that Toll-like receptor 4 (TLR4) acts as the signaling core of the LPS receptor and proposed that other TLRs might also recognize conserved molecular signatures of infection.

Moving in 2000 to the Scripps Research Institute, Beutler developed the largest mouse mutagenesis program in the world, and applied a forward genetic approach to decipher the signaling pathways activated by TLRs. He also identified many other molecules with non-redundant function in the immune response. Returning to UT Southwestern in 2011, he developed a means of instantly identifying mutations responsible for both quantitative and qualitative phenotypes. This allowed rapid discovery of many new components of the immune system.

Beutler is currently a Regental Professor and Director of the Center for Genetics of Host Defense at the University of Texas Southwestern Medical Center. He also holds the Raymond and Ellen Willie Distinguished Chair in Cancer Research in honor of Laverne and Raymond Willie, Sr. Before he received the Nobel Prize, his work was recognized by the Shaw Prize (2011), the Albany Medical Center Prize in Medicine and Biomedical Research (2009), election to the National Academy of Sciences and Institute of Medicine (2008), the Frederik B. Bang Award (2008), the Balzan Prize (2007), the Gran Prix Charles-Leopold-Mayer (2006), the William B. Coley Award (2005), the Robert-Koch-Prize (2004), and other honors.



George Hara 原丈人

**Group Chairman and CEO
DEFTA Partners**

Mr. George Hara is an archaeologist, tech entrepreneur, and venture capitalist.

In Japan, Ambassador Hara served as Senior Advisor to the Ministry of Finance, the Prime Minister's Special Commissioner on the Government Tax Panel, as an advisor to the Ministry of Internal Affairs and Communications, and as a member of various government committees, including Japan's Industrial Structure Council of the Ministry of Economy, Trade and Industry. In these capacities, Ambassador Hara's efforts are aimed at lowering tax rates while increasing tax revenues in order to enable the Japanese government to establish fiscal discipline.

In the private sector, Mr. Hara founded DEFTA Partners in 1984 and became a Partner at Accel Partners in 1990. He was considered one of the most prominent Silicon Valley venture capitalists in ICT in the 1990s and has led more than twenty companies – including Borland, PictureTel, SCO, Tradex, and Unify – to success. Since 2000, Mr. Hara has served as chairman of the board or helped to manage a number of U.S., Israeli and UK companies including Oplus Technologies (Merged with Intel in 2005), Broadware (merged with Cisco in 2007), Transitive Tech (merged with IBM in 2008) and Fortinet (NASDAQ IPO in 2009).

DEFTA Partners has long-term relationship with top universities and research institutes worldwide to commercialize the R&D achievements and to create new industry. Mr. Hara founded DEFTA Partners Hong Kong Office, to invest and to foster next generation of entrepreneurs, to promote collaboration between Hong Kong and Japan, and to make Hong Kong China's international innovation and technology hub. His vision is to make the new technologies and treatments accessible to patients, and thus create a thick layer of healthy and well-educated middle class all over the world.

Mr. Hara currently serves as Chairman of the Alliance Forum Foundation (AFF), a 501(c)3 non-profit organisation in Special Consulting Status with the UN Economic and Social Council. AFF is comprised of a number of divisions, notably the Alliance Forum Development Programme (AFDP) and the Public Interest Capitalism Research Institute (AFPIC). AFDP implements the organisation's international development activities focused on (1) eradicating malnutrition, (2) improving education and health care, and (3) promoting economic self-reliance and empowerment in developing nations. AFPIC, on the other hand, works to conduct research and define models for post-financial capitalism to replace the prevailing shareholder-centric model of capitalism which lies at the root of global financial crises. He has also previously served on the boards of the San Francisco Opera, University of San Francisco, Tokyo Foundation, Japan Society and the Hara Research Foundation.

Mr. Hara was born in Osaka, Japan, in 1952. After graduating from Keio University's Faculty of Law, he became involved in archaeological research in Central America until the age of 27. Following this, he enrolled in the Stanford MBA Programme in California and received a Master of Science degree from the Stanford University Graduate School of Engineering after a period serving as a UN Fellow.

He is also the author of numerous articles and publications, including a Japanese best-seller entitled 21 Seiki no Kokufuron (An Inquiry into the Nature and Causes of the Wealth of Nations in the 21st Century), published by Heibonsha in 2007, and Atarashii Shihonshugi (New Capitalism) published by PHP Institute in 2009. He is a Global Agenda Council Member and a Meta Council Member of Inclusive Growth of the World Economic Forum (Davos Forum), and serves on International Advisory Council of SALK Institute.



Jisheng Han 韩济生

Academician

Chinese Academy of Sciences

Han Jisheng has been studying the principle of acupuncture analgesia from the perspective of central neurochemistry for half a century. He first clarified the time and space distribution rules of acupuncture on human acupoints for analgesia. He found that acupuncture can activate the body's endogenous analgesic system and release He produces opioid peptides, monoamine neurotransmitters and other substances, and is a global leader in the research on the principles of traditional Chinese medicine and acupuncture.

After more than 30 years of clinical practice, he developed a "neuromodulator" that uses transcutaneous electrical acupoint stimulation (TEAS) to treat pain and various other diseases. Under his promotion, the Neuroscience Center of Beijing Medical University was established and developed into the Key Laboratory of Neuroscience of the Ministry of Education and the Key Laboratory of Neuroscience of the Ministry of Health. In addition, he also founded the Pain Branch of the Chinese Medical Association, Beijing Neuroscience Society, China Branch of the International Neuropeptide Association and the Chinese Journal of Pain Medicine.

Since 1979, Academician Han Jisheng has been invited to give 206 lectures at more than 100 universities and research institutions in 27 countries and regions, teaching the principles of traditional Chinese medicine and acupuncture. He served as a scientific advisor to the World Health Organization (WHO) from 1990 to 2002, and a consultant to the US National Institutes of Health (NIH) from 1991 to 2002. He was elected as an international academician of the Royal Academy of Sciences in Lund, Sweden, and the Education Committee of the International Society of Pain (IASP). Member (1991-1995). In 2022, Academician Han Jisheng won the second Sheikh Zayed International Award for Traditional Medicine (TACM2022 International Award).



Jonathan Symonds

Chair
GSK Plc

Sir Jonathan Symonds has extensive international financial, life sciences and governance experience. In July 2021, Sir Symonds co-chaired with Professor Sir John Bell the preparation of the UK Life Science Vision, which sets out a strategy for UK life sciences in the post-Covid world and seeks to capitalise on many of the UK's scientific successes through the pandemic.

In financial services, Sir Symonds served as an Independent Non-Executive Director of HSBC Holdings plc from April 2014, and as Deputy Group Chairman from August 2018, until his retirement from the Board in February 2020. He was previously Chairman of HSBC Bank plc from April 2014 to July 2018 and oversaw the formation of the ring-fence bank HSBC UK plc. He was also a partner and managing director at Goldman Sachs between July 2007 and September 2009.

Sir Symonds was Chief Financial Officer of Novartis AG from September 2009 to January 2014 and Chief Financial Officer of AstraZeneca plc from October 1997 and July 2007, a period which included the negotiation and completion of the merger with Astra. As a CFO, Sir Symonds chaired the 100 Group of Finance Directors, co-chaired the HMRC business tax committee and co-founded the Centre for Business Taxation at the Said Business School.

Prior to joining Zeneca in 1997, Sir Symonds was a Partner at KPMG, specialising in large scale business transformation in the chemicals and pharmaceuticals industries. His additional governance experience includes roles as Non-Executive Director and Chair of the Audit Committees of Diageo plc and QinetiQ Group plc; Non-Executive Chair of Proteus Digital Health Inc; Non-Executive Director, Rubius Therapeutics Inc.



Rao Yi 饶毅

President
Capital Medical University

Yi Rao is the President of Capital Medical University, a Chair Professor and the Founding Director of the PKU-IDG/McGovern Institute for Brain Research at Peking University, the Founding Director of PKU-Tsinghua Center for Life Sciences, and the Founding Director of the Chinese Institute for Brain Research at Beijing.

Rao received medical and graduate training in China from 1978 to 1985. He obtained his PhD from the University of California at San Francisco in 1991 with a thesis on molecular and genetic analysis of cellular communication in *Drosophila* neural development. He was a postdoctoral fellow at Harvard working on molecular mechanisms of neural development in amphibians. He was on the faculty of Washington University School of Medicine from 1994 to 2004 and Northwestern University School of Medicine from 2004 to 2007, where his lab worked on molecular and cellular basis of neural development, revealing the origin of two eyes in a single morphogenetic field, discovering the chemorepellent function of the Slit proteins in axon guidance and neuronal migration, and dissecting signal transduction mechanisms of the chemorepellent Slit and chemoattractant Netrin. His lab has found conserved guidance mechanisms between neurons and leukocytes. In 2007, he returned to China as the Dean of the School of Life Sciences at Peking University. His lab currently investigates molecular and cellular mechanisms underlying behavior and cognition. Rao has proposed the concept of chemoconnectome (CCT) as the entire set of neurotransmitters, neuromodulators, neuropeptides and their receptors underlying chemical transmission in an animal. The Rao lab has invented the generally applicable chemoconnectomics approach and generated new genetic resources to study the functional roles of genes and cells in the CCT, to manipulate chemical transmission and to map neural circuits. In humans, they use genetics, genomics and functional magnetic resonance imaging (fMRI) to investigate genes and brain regions important in cognition. The Rao lab has carried out research with flies, frogs, mice, rats, monkeys and humans to understand fundamental mechanisms both those conserved among animals and those unique for humans.

Rao is instrumental in reforming and establishing several leading institutions of science and higher education in China. He assisted the establishment of the Institute of Neuroscience (ION) of the Chinese Academy of Sciences in Shanghai (1999) and participated in establishment of the National Institute for Biological Sciences (NIBS) in Beijing (2004). He was a co-founder or founder of the Shanghai Institute for Advanced Studies (2002), the Peking-Tsinghua Center for Life Sciences (2011), the PKU-IDG/McGovern Institute for Brain Research (2012) and the Chinese Institute for Brain Research, Beijing (2018). He is a co-founder of the Westlake University. He is a founding member of Scientific Committee of the Future Science Prize of China (2016), and a co-founder of the Xplorer Prize for Science and Technology of China (2018). He joined the Medical Advisory Board of the Canada Gairdner International Award in 2018.

Rao has taught courses in neurobiology, genetics, developmental biology, molecular biology, cell biology and pharmacology. He has continuously taught the course Concepts and Approaches in Biology (CAB) since 2008, focusing on classic experiments in genetics from Mendel (1866), Miescher (1871), Morgan (1910), Griffith (1928), to Avery, MacLeod and McCarty (1944), in developmental biology from Roux (1888), Spemann and Mangold (1924), Lewis (1978) to Nusslein-Volhard and Wieschaus (1980), in neurochemistry from Bernard (1857), Langley (1901), Elliot (1905) to Dale (1910) and Loewi (1921), in electrophysiology from Adrian (1912), Hodgkin and Huxley (1939), Katz (1952), to Hubel and Wiesel (1962), and in immunology from Behring and Kitasato (1890), Ehrlich (1900), Owen (1945) to Burnet (1959).

BIOHK AUDITORIUM | BIOHK 會堂

Healthy Aging and Longevity

Wednesday, September 13 | 12:40 PM - 18:00 PM (GMT+8)

12:40 - 12:50	Sponsor: HK Longevity Medical Center Chair: Dr. Christine Huang, HK Longevity Medical Center Opening Speech: Mr. Amir Lati, CG Israel
Session One: Aging Biology and AI-Driven Longevity	
12:50 - 13:10	Biomarkers of Human Aging and Geroprotectors Dr. Alexey Moskalev, Komi Scientific Center, Russian Academy of Science
13:10 - 13:30	Prof. Wang Xin, Chinese University of Hong Kong
13:30 - 14:00	Lunch Break
14:00 - 14:15	Prof. Zhongjun Zhou, The University of Hong Kong
14:15 - 14:30	Dr. Dajun Chai, Fujian Medical University
14:30 - 14:45	Mr. Mike Crichton, GSK plc*
14:45 - 15:10	Panel Discussion: Longevity Investment Panelists: Dr. Hank Wuh, Longevity X Mr. Phil Newman, Longevity Technology Mr. Chew Thian, Polar Ventures Mr. Sergey Jakimov, LongeVC
Session Two: Reproductive Longevity and Women's Health	
15:10 - 15:25	The Importance of Female Hormones for Health and Healthy Longevity Prof. Jaron Rabinovici, Sheba Medical Center
15:30 - 15:50	Micro Devices for Aging-related Diseases Dr. Arthur Yang Zhang, Westlake Medical Sci. Ltd.
15:50 - 16:10	Slowing Aging through Mitochondria Prof. Xiangjun Chen
Session Three: Healthy Aging and Longevity Medicine	
16:10 - 16:30	Mitochondrial DNA Mutation and Disease: Young and Old Dr. Zhenglong Gu, Cornell University
16:50 - 16:05	DNAm Clocks and Reversing Biological age Prof. Hidekazu Yamada, Japanese Society of Anti-Aging Medicine
16:05 - 17:20	Practice of Longevity Medicine in Japan Prof. Yoko Masuda, Japanese Society of Stem Cell Supernatant for Clinic*
17:20 - 17:35	The Art and Science of Super Longevity: Top Tips for Bioentrepreneurs to Extend Lifespan and Health span to 120 Years Old while Enhancing Productivity and Peak Performance Dr. Mark Tang, Good Health Capital
17:35 - 17:50	NAD+ Detection Probe Combines AI in Anti-Aging Drug Discovery Dr. Juliane Hitzel, CellFull
17:50 - 18:00	Closing Remarks Dr. Christine Huang, HK Longevity Medical Center

*No biography or information was provided before September 01, 2023.

Sponsored by HK Longevity Medical Center

至善·创新·健康

以患者为中心，追求更高标准的社会价值输出

COMPANY PROFILE

企业简介

康诺亚生物医药有限公司(2162.HK)立足创新、专注研发，致力于为患者提供更多高质量、可负担的创新疗法，解决亟待满足的临床需求。

CORE AREAS

核心领域

聚焦自身免疫及肿瘤领域 康诺亚搭建起具国际竞争力的产品管线
高效推进多项多元化、差异化的创新产品临床研究



CORE PRODUCTS

核心产品

CM310

IL-4R α 抗体

- 获 CDE 突破性治疗药物认定
- 即将递交用于成人中重度特应性皮炎治疗的上市申请

CMG901

Claudin 18.2 ADC药物

- 获 CDE 突破性治疗药物认定、FDA 快速通道及孤儿药资格认定
- 已与阿斯利康达成全球独家授权协议



Christine Yuan Huang 黄园

**Founder and Managing Director
HK Longevity Medical Center**

As a serial MedTech / biotech entrepreneur with a medical background, Dr. Christine Yuan Huang has devoted herself to bringing cutting-edge technology from the laboratory to clinical use and further commercialization, to help more people facing life-threatening illnesses.

Dr. Christine Huang Yuan was selected as one of Forbes China 2020 “30s Under 30 (Healthcare and Science)”. Dr. Huang has vast experience in the biotechnology field and shares her professional insights as a biomedicine investment consultant for China Internet Investment Finance Holding Limited (stock code: 0810. HK). She is also a Fellow of The Royal Society of Medicine(UK). She is also a member of the Advisory Board of Wing Wah Charity Foundation Hong Kong.

In May 2021, Christine, together with other international experts, developed and recorded the “Introduction to Longevity Medicine for Physicians course in Chinese”, which has a concise three-hour curriculum designed to familiarize busy medical professionals with the latest advances in aging research (focusing on biomarkers of aging and longevity).



Amir Lati 藍天銘

**Consul General of Israel
Consulate General of Israel**

Mr. Amir Lati has been Consul General of the State of Israel in Hong Kong SAR and Macao SAR since September 2021. A graduate of B. A. in Economics and East Asian Studies at the Hebrew University, Jerusalem, Mr. Lati pursued his interest in Chinese Studies at Beijing University under a Chinese Government Scholarship. His further studies included MA in Democratic studies at the Open University of Israel as well as an MBA in Finance and Organizational Behavior at Tel Aviv University. Since joining Israel’s Ministry of Foreign Affairs in 1999, Mr. Lati served at the Embassy of Israel in Abuja, Nigeria (2001) and Canberra, Australia (2003); at the Ministry of Foreign Affairs headquarters in Jerusalem (MFA) as Deputy Director of West and South Africa, African Division (2005-2006); Deputy Consul General of Israel in Shanghai (2006-2010) and Consul General in Chengdu (2014-2018). From 2019 till his arrival in Hong Kong, Mr. Lati was the Director, the North East Asia department, Asia and Pacific division in Israel’s MFA. He speaks Hebrew, English, Proficient Chinese and basic Korean.



Alexey Moskalev

Director

Institute of biogerontology of Nizhny Novgorod University

Alexey Moskalev is a Corresponding Member of the Russian Academy of Sciences, Doctor of Biology and the Head of the Laboratory of Geroprotective and Radioprotective Technologies in the Institute of Biology at the Federal Research Center Komi Scientific Centre of the Russian Academy of Sciences.

Alexey is the author of more than 200 publications on the genetics of ageing, longevity and radiation genetics. He focuses on the effects of low-dose ionising radiation on lifespan and ageing of *Drosophila* strains with defects in apoptosis, DNA repair and defence genes. He also studies ageing, longevity and stress resistance mechanisms in animals. He also contributed to creating a database of biomarkers of ageing called the Digital Ageing Atlas and databases of anti-ageing drugs Geroprotectors.org and DrugAge.

He is a member of the editorial boards of *Ageing Research Reviews*, *Aging*, *Biogerontology*, *Frontiers in Genetics of Aging*, *Aging and Disease*, *Gerontology* and *Advances in Gerontology*. He established the international symposium series "Genetics of Ageing and Longevity," "Biomedical Innovation For Healthy Longevity," "Interventions to Extend Healthspan and Lifespan," and "Longevity Interventions 2020".

Alex is the Head of the Komi branch of the Vavilov Society of Genetics and Breeders, a Member of the Central Council of the Society, and Vice President of the Gerontological Society of the Russian Academy of Sciences and the Head of the Department of Ecology of the Syktyvkar State University.



Xin Wang 王鑫

Associate Professor

Department of Surgery, The Chinese University of Hong Kong

Prof. Xin Wang obtained his PhD in 2014 from the University of Cambridge Department of Oncology and Cancer Research UK Cambridge Institute. From 2013 to 2015, he did his postdoctoral research at the Department of Biomedical Informatics, Harvard Medical School. He is currently an Associate Professor at the Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong. He also serves as a consultant for Shanghai Artificial Intelligence Laboratory, and an academic committee member of Guangdong Key Laboratory of Human Disease Genomics. Prof. Wang's group has been focusing on mechanistic and translational research in major human diseases through large-scale data mining using novel methodologies integrating bioinformatics, systems biology, machine learning, and artificial intelligence. Prof. Wang published > 90 peer-reviewed papers in journals such as *Nature Medicine*, *Gastroenterology*, *Hepatology*, *Molecular Cancer*, and *Annals of Surgery*. His research is currently funded by Research Grants Council of Hong Kong, Shenzhen City and Guangdong Province.



Zhongjun Zhou 周中軍

Professor

School of Biomedical Sciences, The University of Hong Kong

Zhongjun Zhou is currently a professor at the department of Biochemistry, The University of Hong Kong. He graduated from Xiamen University with a BSc in Biochemistry. He obtained Master of Science in Biochemistry and PhD in Pathophysiology from Peking Union Medical College. He also obtained a PhD degree in Medical Biochemistry from Karolinska Institute, Sweden. After postdoctoral training in Karolinska Institute, he joined the department as a Research Assistant Professor in 2002 and became Associate Professor in 2005. He has published more than 40 original papers, reviews and book chapter. He is the co-founding Chair of Asian Association of Aging Research.



Dajun Chai 柴大军

Vice President

First Clinical College of Fujian Medical University

Chai Dajun, born in 1975, doctor of medicine, chief physician, professor, doctoral supervisor, vice president of the First Clinical College of Fujian Medical University, visiting scholar of the Berlin Heart Center in Germany, expert member of the American College of Cardiology (FACC), Fujian Provincial Health System academic technology leader, technical director of the Chest Pain Center (National Demonstration Center) of the First Affiliated Hospital of Fujian Medical University, director of the Atrial Fibrillation Center; communication review expert of the National Natural Science Foundation of China, coronary interventional diagnosis and treatment training instructor of the National Health Commission, "Chinese Heart Editorial board member of "Journal of Vascular Diseases" and "Chinese Journal of Hypertension"; national youth committee member of the Cardiovascular Disease Branch of the Chinese Medical Association, deputy director of the Fujian Cardiovascular Branch of the Chinese Medical Doctor Association, and standing member of the Fujian Cardiovascular Branch of the Chinese Medical Association. Executive Vice Chairman of the Youth Committee of the Fujian Cardiovascular Branch of the Chinese Medical Association, Standing Member of the Fujian Cardiovascular Branch of the Society of Integrated Traditional Chinese and Western Medicine, Executive Deputy Chairman of the Youth Committee of the Fujian Cardiovascular Branch of the Society of Integrated Traditional Chinese and Western Medicine, Cardiac Rehabilitation Branch of the Society of Integrated Traditional Chinese and Western Medicine Standing committee member. Specializes in interventional therapy of complex high-risk coronary artery disease and treatment of critically ill patients.



Thian Chew

Adjunct Associate Professor

The Hong Kong University of Science and Technology

Professor Chew holds the position of Executive Chairman & Chief Executive Officer for Invion Ltd. and Chairman of Chronic Airway Therapeutics.

He is also Managing Partner at Polar Ventures Ltd.

He received an MBA from The Wharton School of the University of Pennsylvania, a graduate degree from Joseph H Lauder Institute of Management & International, and an undergraduate degree from Monash University.



Phil Newman

Editor-in-Chief
Longevity Technology

Phil Newman is Founder and CEO of www.Longevity.Technology the leading media and investment platform targeting the longevity megatrend.

In his career he has held multiple c-level management positions; applying his marketing and business development expertise into: longevity, IoT, bionics, medical devices, biopharma, 3D manufacturing, smartgrid and sustainability.

In 2018 he saw an opportunity in the emerging longevity field to create a media platform that addressed science, business and investment activity. Launched in 2019, www.longevity.technology rapidly became the leading news service with unparalleled domain authority enabling the company to expand its reach into investment, education and commerce.



Hank Wuh

Co-Founder of Longevity X
Board Trustee
University of Hawaii Foundation

Hank Wuh, MD, MPH is an orthopedic surgeon, inventor, and serial entrepreneur. He has led the development of over twenty biomedical and consumer healthcare products from inception to market. Dr. Wuh nurtures entrepreneurs to transform ingenious, “unthinkable” ideas into disruptive innovations and high growth companies with global impact that makes the world a better place.

Dr. Wuh received his BA from Johns Hopkins, MPH from Harvard, MD from the Johns Hopkins School of Medicine, and orthopedic surgery residency at Stanford. He speaks fluent Mandarin and is an avid musician and traveler. An accomplished public speaker on the transformative power of ideas, Dr. Wuh was selected 100 of the most intriguing entrepreneurs in the world in 2016 by Goldman Sachs, and has served as a keynote speaker and Technology Pioneer at the World Economic Forum in Davos.



Sergey Jakimov

Managing Partner
LongeVC

Sergey is a serial entrepreneur, having co-founded 3 deep-tech ventures (including Koatum and Vortex Oil Engineering) and raised more than \$50 million in venture funding. He has advised several other startups in the therapeutics space on fundraising, IP protection, and clinical trial strategies. He is also a Visiting Lecturer to several universities on venture capital and intellectual property rights and co-authored a master's program in Technology Law for the Riga Graduate School of Law.

Since 2018, he has led medical tech startup Longgenesis, a cutting-edge company that unlocks the hidden value of biomedical data and accelerates novel drug treatment & discovery. Sergey holds a BSc in International Affairs from Riga Stradiņš University and two MSc in Political Science and Government and Law and Finance from Central European University and Riga Graduate School of Law, respectively. He was named as a Forbes Latvia 30 Under 30 in technology and healthcare in 2020.



Jaron Rabinovici

**Associate Professor Deputy Chairman, Dpt. Obstet&Gynecol
Sheba Medical Center**

Prof. Rabinovici is an experienced MD Professor in Obstetrics Gynecology and Infertility with a demonstrated history of Clinical Care as well as work in the higher education industry. Prof. Rabinovici is a highly-trained specialist, who provides medical treatment for women and couples with infertility, and performs pregnancy (including at-risk pregnancies) surveillance. Prof. Rabinovici specializes in diagnoses and treatment of fertility problems in women and men. He has extensive experience in IVF (IVF), egg donation, ovulation, insemination, uterine imaging, and recurrent miscarriage treatment. He is an expert in non-invasive conservative treatment of uterine fibroids. He is the head of the Department and Vice-Chairman of the Division of Obstetrics and Gynecology at the Chaim Sheba Medical Center, Israel. He is also a professor at Sackler School of Medicine, Tel Aviv University, Israel.

Prof. Rabinovici authored more than eighty original scientific papers in leading Medical Journals. He has been invited to many lectures around the world. Involved with Biotech and Biomed Companies as Counselor, Board member and Investor.



Yang Zhang 张杨

**CEO
Westlake Medical Sci. Ltd**

Arthur Yang Zhang, PhD MBA: Dr. Zhang is a MedTech entrepreneur and the founder of Westlake Medical Sci. Ltd. The series B startup focuses on MEMS technology applications in medical treatments. Dr. Zhang invented world's first μ RFthera system for Overactive Bladder (OAB) that has been adopted by over 15 leading public hospitals. Over 450 severe OAB patients received this procedure with over 75% of efficacy in reducing episodes to normal situations. The microRF technology also has profound impact in antiaging purposes. Dr. Zhang is the author of over 20 articles on international journals, and the inventor of over 40 international patents on micro devices. Prior to his entrepreneurial effort, Arthur served as Partner of Plug and Play Tech Center, technical director of Calit2 Irvine as well as Postdoc Researcher at the Integrated Nanosystems Research Facility. Dr. Zhang's Ph.D. work at UC Irvine and UCLA Large Plasma Device was supported by a Regents' Fellowship and a Department of Energy grant. Arthur also received an MBA from UCLA Anderson School of Management, with a concentration on entrepreneurship.



Xiangjun Chen 陈向军

Professor

**China National Clinical Research Center for Neurological Diseases,
Capital Medical University**

Xiangjun Chen, M.D., Ph.D., is an accomplished professional with multiple roles and responsibilities within the medical and research fields. Currently, he serves as the Deputy Head of Scientific Research at Fudan University Shanghai Medical School. In addition, he holds the positions of Professor of Neurology, Chief Physician, and Doctoral Supervisor. Within Fudan University, Chen holds significant leadership roles as Vice Chair at both the Institute of Neurology and the Institute of Rheumatology, Immunology & Allergy. He is also a Principal Investigator at the Human Phenome Institute and serves as the Deputy Director of the Huashan Hospital Core Laboratory.

Recognized for his expertise and contributions, Chen has been honoured as a Shanghai "Pu-Jiang Talent." He actively participates in professional societies, as evidenced by his positions as Deputy Secretary General of the 12th Council of the Shanghai Immunology Society and Chairman of the Neuroimmunology Committee within the society. Additionally, he is a Council Member of the Chinese Society for Immunology.

Chen's involvement extends globally as a Committee Member of the International Peripheral Nerve Society. Furthermore, he contributes to the development of standards in his field as a Committee Member of the Standardization Administration of China (SAC/TC559). With his diverse roles, extensive experience, and active engagement, Xiangjun Chen has established himself as a respected leader and researcher in the fields of neurology, immunology, and medical science.




Zhenglong Gu 顾正龙

Director

Mitochondrial Genetics and Health Research Center

Zhenglong Gu, Ph. D., obtained his Ph.D. from the University of Chicago, USA, in 2003 and Bachelor from Beijing University, China, in 1998. He did his postdoc training at Stanford University before he setup his own lab at Cornell University in 2006. He obtained his tenure and full professorship in 2012 and 2018, respectively. Currently his major goal in research is to understand the role of mitochondrial DNA mutation in diseases. He started at Cornell investigating the evolution of aerobic fermentation in yeasts and became interested in mitochondrial genetics purely because he was fascinated by the metabolic similarity between yeast evolution and tumorigenesis (the emergence of Warburg Effect). Recently, his lab has been working on several issues that are critical to demonstrate the important role of mitochondrial DNA (mtDNA) mutations in diseases, including inventing various sequencing methods to reveal mtDNA mutation pattern during aging and in age-related diseases, developing tools for mtDNA genetic manipulation so mechanic studies can be conducted directly upon mtDNA mutations, and investigating mechanisms underlying mutated mtDNA purging.



Hidekazu Yamada 山田秀和

Professor

President of Japanese Society of Anti-Aging Medicine

A leading expert in anti-aging research, serving as the president of the Japanese Society of Anti-Aging Medicine. Currently, he is focusing not only on researching “appearance”, but also investigating the mechanism of epigenetics, which controls the function of genes. In 2025, he will also serve as a member of the Osaka Pavilion Promotion Committee and Director of Healthcare Advanced Preventive Medicine at the Osaka/Kansai Expo.



Mark Tang

Managing Director

Good Health Capital (New York)

Dr. Mark Tang has followed and invested in the life sciences biotech industry for over a decade. He has been a senior biotechnology analyst, venture capitalist, wealth management advisor, and Publisher of Bio/Medical Technology Stock Newsletter. Dr Tang has also worked for several investment banks including UBS PaineWebber and Morgan Stanley Dean Witter in New York, and currently heads a healthcare life sciences venture investment firm in the United States.



Juliane Hitzel

**Senior Researcher, Institute of Mitochondrial Medicine
CELLFULL**

Dr. Juliane Hitzel, is a Senior Researcher of the Institute of Mitochondrial Medicine, CELFULL, a member company of BritCham Guangdong. As a young female scientific researcher with outstanding achievements in the field of biotechnology, Dr. Hitzel first shared the challenges and breakthroughs she faced in dealing with numerous research projects and cross-cultural teamwork during her Ph.D. studies. After joining CELFULL, she led the team to conquer the mitochondrial anti-aging scientific and technological topics with her professional qualities, rational thinking, and delicate thoughts as a woman. At the end of her speech, Dr. Hitzel welcomed all female friends present to join the Hebe PLAN, a mitochondrial research project of CELFULL, to challenge themselves in unlocking the human anti-aging mystery and to help promote the scientific development in this field.

INNOVATION GALLERIA | 創新廊

Thrive in the Biotech Market

Wednesday, September 13 | 12:40 PM - 17:00 PM (GMT+8)

Investing in Life Science In Hong Kong (Sponsored by SCMP)

12:40 - 13:30

Chair: Ms. Elizabeth Cheung, South China Morning Post (SCMP)

Panelists:

Sir. Jonathon Symonds, GSK
Mr. Conrad Tsang, Hong Kong Venture Capital and Private Equity Association (HKVCA)
Mr. Aaron Finley, Deloitte
Mr. Frank Yang, Bank of China Group Insurance (BOCG)

13:30 - 14:00

Lunch Break

Policy Foundations for a Life Science Ecosystem in Hong Kong and GBA

14:00 - 15:30

Chair: Dr. Joe Fang, One Country Two System Research Institute

Moderator: Dr. Hon Yuen-shan Wong, Chief Executive's Policy Unit

Panelists:

Ms. Maggie Lo, Office for Attracting Strategic Enterprises (OASES)
Prof. Yuk Lam Lo, HK Bio-Med Innotech Association (HKBMIA)
Dr. Sabrina Chan, HKAPI
Mr. Vincent Ma, Hong Kong-Shenzhen Innovation & Technology Park (HSTIP)
Mr. Arthur Tsang, Hong Kong Biotechnology Organization (HKBIO)
Mr. Raymond Yip, Nansha New Area
Dr. Yu Guoliang, Bay Helix Group

HKEX Special Program

16:00 - 17:00

Keynote: Dr. Shusong Ba, HKEX

Moderator: Ms. Winnie Han, HKEX

Panelists:

Ms. Lynne Wu, LongevityX*
Ms. Mengyang Wang, China International Capital Corporation (CICC)
Mr. Andrew Ng, VMS Group
Dr. Chang Liu, ASK Health

**No biography or information was provided before September 01, 2023.*

Sponsored by



South China Morning Post

BIOHK2023 GOLD SPONSOR



上海生物医药基金

上海生物医药基金是经上海市政府批准，由上实集团发起设立，目标规模人民币500亿元的创新投资平台，基金坚持“立足沪港、联动长三角、面向全球”，并将在香港发起专注于香港及大湾区生物科技产业的早期创新基金，助推生物科技产业成为香港经济增长的新引擎。



鸿坤产业
HONGKUN
BUSINESS PARK

鸿坤产业集团

鸿坤产业投资发展集团（以下简称“鸿坤产业”），致力成为中国领先的创新产业园区运营商。

作为鸿坤控股旗下面向未来战略的重要业务集团，鸿坤产业秉持“打造产业生态，提升城市价值”的发展理念，以产业园开发、产业投资和产业运营三大业务板块全面构筑产业生态创新发展。

聚焦“科技创新、创意创新、孵化创新”三大产业方向，鸿坤产业积极布局国家战略性新兴产业、文化创意产业、现代服务业等重点产业，并围绕国家战略重点区域，夯实巩固首都核心区，积极布局京津冀，开拓辐射长三角、珠三角、成渝、武汉等区域；先后成功开发建设、运营投资鸿坤·金融谷、鸿坤·云时代、亦庄鸿坤·智谷、马驹桥鸿坤·智谷、西红门·鸿坤智谷等产业园项目。目前，产业园区资产规模已达 300 万平方米。



未来，鸿坤产业将延续“创新驱动、共享开放”的价值理念，以构建“产业+基金+园区”的驱动模式和完善“企业发展服务生态体系”，培育特色产业集群在城市中的发展，在推动企业发展的同时，实现产业转型升级，促进区域经济增长，激发城市活力。



Elizabeth Cheung

Correspondent
South China Morning Post

Elizabeth is currently a correspondent covering Hong Kong healthcare news at the South China Morning Post. A seasoned journalist with over 10 years of experience in newspaper and television, Ms. Cheung has been writing about healthcare news, from policies to scientific research, since 2014. During the Covid-19 pandemic, she was one of the journalists leading the Covid-19 coverage at the Post, breaking news of the latest government measures and writing long-form analyses. Elizabeth is a graduate of the Chinese University of Hong Kong's School of Journalism and Communication, and has a Master's in development studies from the London School of Economics and Political Science.



Conrad Tsang

Founder and Chairman
Strategic Year Holdings

Mr Tsang has been in the private equity and venture capital industry for over 20 years. Mr Tsang's industry experience includes: environmental technologies, healthcare, education and professional services, TMT, financial services, retail and consumer products/services, advanced manufacturing, automotive, ecommerce/logistics, energy and alternative energy, real estate, natural resources/mining etc. The companies he has been involved with include Noah Education Holdings Limited, Minsheng Education Group (1569.HK), Galloping Horse Media Group Limited, Kangda International Environmental Protection Holding Limited (6136.HK), Pansoft Group Limited, Ambow Education, Hidili Industry International Development Limited (1393.HK), Launch Tech Co Ltd (2488.HK), Great Wall Auto (2333.HK, 601633.CN), Nord Anglia Education, China Mini-Storage, Teky Holdings, Carsome, Cakap, Sayurbox, Halodoc, Haus!, Buyandship, AMPD Energy. Prior to founding Strategic Year Holdings Limited, he spent 13 years at Baring Private Equity Asia ("Baring Asia"), where he was Managing Director. He was the Founding Partner of Baring Asia's Beijing office. Prior to that, he was with Merrill Lynch Asia Pacific doing equity research, focusing on media and retail sectors. Since 2016, he became Founder and Chairman of Strategic Year Holdings Limited.

Mr Tsang is currently President and Director of the Hong Kong Venture Capital and Private Equity Association (HKVCA). Previously, he was Hong Kong Venture Capital and Private Equity Association's Chairman of the Board (2013-2015). He was voted one of "The 50 Best Venture Capitalists in China" by Forbes China Magazine (2008, 2009). Mr Tsang is a Member of Oxford Investment Opportunity Network (OION), Member of Imperial College Investor Network, and Member of Hong Kong Cyberport Investor Network (CIN). He was also invited to serve as Asia Senior Advisor of Apollo Education Group/Apollo Global, a global higher-education company.

Mr Tsang obtained a Master's Degree in Management Studies at University of Oxford, United Kingdom; and a Bachelor's Degree in Electrical and Electronic Engineering (First Class Honors) at Imperial College of Science and Technology, London, United Kingdom. He also completed an executive program on Private Equity and Venture Capital at Harvard Business School, US.



Aaron Finely

Director
Deloitte China

Aaron is a Director in Deloitte's South China Business Development team based in the Guangzhou office. With a diverse network and broad experience in international business, Aaron helps his clients in developing best practices for international business, accounting, taxation, as well as seek investment and development opportunities. Aaron is also supporting the Deloitte's Greater Bay Area (GBA) Initiative and is leading the development of a hospital collaboration platform so that hospitals around the GBA can better coordinate best practices. Aaron is a licensed CPA in California and has obtained a Masters in Business Taxation from the University of Southern California. Aaron is a Part-Time Lecturer on International Taxation and PhD Student at the Macau University of Science & Technology. Aaron is a member of the Board of Governors of AmCham South China and is a member of the board of the European Chamber of Commerce South China Chapter. He is an Advisor to the Guangdong Investment Promotion Association, an expert of the Guangzhou Capital Market Pool, and a contributor to the Guangzhou City Business Environment Study.



Frank Yang 楊鋒

Founding Partner and CEO
Blue Ocean Capital Group

Mr. Yang is the founding partner and CEO of Blue Ocean Capital Group ("BOCG"). He has over 20 years of experience in venture capital and private equity investment with US\$ 1 billion proven track records. He led a symbolic US\$ 250 million cross-border healthcare M&A which won him distinguished awards including "the Top 10 Private Equity Investments in China" and "the Best M&A Financing Award" of the year.

Before Mr. Yang founded BOCG, he served as the managing director of China Construction Bank International ("CCBI"), in charge of healthcare investment with dual currency funds. Prior to that, as head and managing director of PPF Group, a leading financial institution in Central and Eastern Europe, Mr. Yang was responsible for strategic investment in Asia and contributed to the establishment of HomeCredit China. Mr. Yang's finance career started in 2001 when he served as a founding member and vice president of the venture capital investment arm of Xiangcai Securities, where he succeeded in raising fund and achieving a 6X return on investment.

Mr. Yang Feng is committed to the transformation of scientific research achievements of biotechnology with a focus on promoting transformation of R&D and cooperation in Asia and globally. Mr. Yang has been promoting corporate governance in the pharmaceutical industry in both practices and theoretical level, and had published numerous research papers in both Chinese and English and made speeches. With Mr. Yang's initial, BOCG joined the Responsible Investment Organization supported by the United Nations ("UN PRI"), among the first batch of signing investment institutions in China to promote ESG and sustainable development.

Recent healthcare investments led by Mr. Yang including Hightide Therapeutics, Ribo Life Science, Boan Biotech, CureGenetics, Koko Life Science, Signet Therapeutics, InterHill MED and Recovery Plus etc. Mr. Yang sits on the board of HK Bio-Med Innovation Association ("HKBMIA"), Chinese Financial Association in Hong Kong ("HCFA"), PRC Committee of Hong Kong Venture Capital and Private Equity Association ("HKVCA"), and the advisory board of HKUST MBA Business School.

Mr. Yang is a PhD candidate of CUHK and holds the MBA degree from HKUST with exchange experience in Columbia University in New York and HHL Business School in Leipzig.



Joe Fang 方舟

Chief Research Officer
One Country Two Systems Research Institute

Dr. Joe Z. Fang is the Chief Research Officer of the One Country Two Systems Research Institute. He has rich research experiences in industrial policy, international relations, urban planning, and regional economic development of Hong Kong and mainland China. Dr. Fang actively participates in various public services. He is the Convener of the Trade Facilitation Committee of the HKSAR Consultative Committee on Economic and Trade Co-operation between Hong Kong and the Mainland. He is also a member of Lantau Development Advisory Committee, Shenzhen Internationalization Advisory Committee, Shenzhen People's Consultative Committee, and Advisory Committee of Qianhai Authority.



Stephen Wong 黄元山

Head
Chief Executive's Policy Units

Dr. Stephen Wong received his Bachelor of Arts (Phi Beta Kappa) in Economics from the University of Chicago and took his Master of Arts in East Asian Studies (Whitney and Betty MacMillan Center for International and Area Studies) from Yale University and earned his Doctorate degree in Public Administration (DPA) from The University of Hong Kong.

Dr. Stephen Wong began his career as an investment banker; he was in managerial roles with several global financial institutions, including as Executive Director at UBS (London) and Managing Director at RBS. He joined Our Hong Kong Foundation (OHKF) as Senior Consultant in May 2015 and was appointed Deputy Executive Director cum Head of Public Policy in November the same year. He was Senior Vice President & Executive Director of Public Policy Institute. He was appointed as the Head of Chief Executive's Policy Units on 27 December.

Mr. Wong's public service also includes various advisory roles appointed by the Hong Kong Government, including Board Member of the Financial Services Development Council, Board Member of the Urban Renewal Authority, Member of the Investment Committee of the Beat Drugs Fund, Member of Investment Sub-Committee of the Housing Authority, Member of Feasibility Study Working Group of "Special Needs Public Trust", Co-opted Member of Social Innovation & Entrepreneurship Development Fund Task Force of Commission on Poverty, Non-official Member of the Assessment Panel of the "Innovation and Technology Fund for Application in Elderly and Rehabilitation Care" of the Social Welfare Department, and ex-Member of Task Force on Land Supply, etc.

Mr. Wong is also active in community service. He is Chairman of the Clean Air Network, Vice Chairman of the Admissions, Budgets & Allocations Committee and Investment Sub-Committee Member of the Community Chest, and Executive Committee Member & Chairman of the Advisory Committee of Social Enterprise and Innovation Platform of the Hong Kong Council of Social Service. Mr. Wong is also an Adjunct Associate Professor at the Hong Kong University SPACE for the Institute for China Business.



Sabrina Chan

Senior Executive Director
Hong Kong Association of Pharmaceutical Industries

Sabrina is the Senior Executive Director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI); member of the High Level Steering Committee on Antimicrobial Resistance; member of Business Facilitation Advisory Committee; Chair of Advisory Board of the HKU Bachelor of Pharmacy Program, Adjunct Assistant Professor of CUHK School of Pharmacy; and member of APEC Biopharmaceutical Working Group on Business Ethics.

Prior to joining the pharmaceutical industry, she was with the External Affairs Department of i-CABLE Communications Ltd. and was responsible for government relations, regulatory issues, corporate affairs, and the promotion of the company's core products and services. She co-founded the Telecommunications Research Project under Centre of Asia Studies (HKU), and was a journalist at various print and electronic media outlets. Sabrina studied Communications in Hong Kong when she began her tertiary education. She holds a graduate degree in International Studies from the University of Sheffield (UK), as well as law degrees from the CUHK and University of Tsinghua (China).



Yuk Lam Lo 盧毓琳

Chairman
Food and Environmental Hygiene, Food and Health Bureau, Government Secretariat HKSAR

Yuk Lam Lo is a highly accomplished individual with a multitude of roles and affiliations. He serves as the Chairman of Food and Environmental Hygiene within the Food and Health Bureau of the Hong Kong Special Administrative Region (HKSAR) Government Secretariat. Additionally, he holds the position of President at the HK Bio-Med Innotech Association, where he spearheads initiatives to promote innovation in the biotechnology and medical fields in Hong Kong.

Yuk Lam Lo's expertise extends to the corporate sector, as he serves as an Independent Director for several prominent companies. He holds this role at Sinovac Biotech Ltd., a leading biopharmaceutical company listed on the NASDAQ stock exchange. He also serves as an Independent Director for CSPC Pharmaceutical Group Limited and Luye Pharma Group Limited, both of which are renowned pharmaceutical companies listed on the Hong Kong Stock Exchange.

Furthermore, Yuk Lam Lo takes on the responsibility of Chairman at GT Healthcare Capital Partners, contributing his expertise to the company's healthcare investment and capital management endeavors. He is recognized as the Honorary Chairman of the Hong Kong Biotechnology Organization, highlighting his influential contributions to the biotechnology sector in Hong Kong.

In recognition of his outstanding achievements, Yuk Lam Lo has been appointed as an Honorary Fellow by the Hong Kong University of Science and Technology. Additionally, he holds a Council Member position in the Chinese People's Political Consultative Conference, representing Jilin Province.

Yuk Lam Lo's diverse roles and accomplishments across government, academia, and the corporate world demonstrate his exceptional leadership and expertise in the fields of public health, biotechnology, and pharmaceuticals.

**Let's talk
business.**

**Let's talk
Vienna.**



**Health
Metropolis
Vienna**

Vienna Startup Package

- 4-week program to identify business opportunities
- Travel expenses covered
- Individual business coachings

Find us at our stand: 3E-A3

**vienna
business
agency**



Vincent Ma

CEO

Hong Kong-Shenzhen Innovation and Technology Park Limited

Mr. Vincent Ma Wai-shin has over 30 years of extensive experience in the Information and Communication Technology (ICT) industry. He has led and managed sizable technology groups and drove the continuous and comprehensive growth of the groups' business. From 2006 to 2019, Mr. Ma served as the President and then the Chief Executive Officer of WTT Hong Kong Limited. Before joining HSITPL, Mr. Ma served as the Chief Digital Officer of Sun Hung Kai Properties.

Mr. Ma holds a Bachelor's Degree in Computing Studies from the Hong Kong Polytechnic University.



Arthur Tsang

Researcher

Our Hong Kong foundation

Arthur oversees a wide range of research topics in tech innovation, and has recently co-authored research reports on biotechnology and gerontechnology. His research projects were commissioned by the UNESCAP, PRC Ministry of Science and Technology, CPC Shenzhen Municipal Committee, Hong Kong SAR Government, Alibaba Entrepreneurs Fund, and he has collaborated with the UN Population Fund China, China National Committee on Ageing, China Center for International Economic Exchanges, China Development Institute (Shenzhen), Hong Kong Science and Technology Parks Corporation, and Hong Kong Council of Social Service, etc.

He has presented at Revive Tech Asia and BIOHK and served as a discussant at the GBA Talent Forum of the Hong Kong Science and Technology Parks Corporation and the Shenzhen-Hong Kong Expert Forum by Baolong District, Shenzhen. He was also invited by Legislative Councillors, the Hong Kong Police Force and Hong Kong CPPCC Youth Association to deliver sharing. His articles frequently appear on major newspapers, with dedicated pages on Ta Kung Pao, HK Economic Times, South China Morning Post, and China Daily.

He is also a research committee member of the Hong Kong PropTech Association and serves in district positions. He holds a bachelor's degree from the University of Hong Kong and a master's degree from the London School of Economics, and has represented OHKF to complete courses with the National Academy of Governance.



Raymond Yip 叶泽恩

Chief Liaison Officer, Guangzhou Nansha Service Centre in Hong Kong
Chief Representative, Hainan International Economic Development
Bureau HK Office

Since July 2022, Mr. Yip serves as the Chief Representative and Chief Liaison Officer for Hainan International Economic Development Bureau and Nansha New Area respectively in Hong Kong. He is also EVC of Dashun Foundation and VC of Belt and Road Global Development Alliance since 2019. He retired from the Hong Kong Trade Development Council as Deputy Executive Director, spearheading promotions for the Belt and Road and Greater Bay Area Initiatives, among other marketing duties, in the same year. He was Part-time Lecturer on BRI and GBA opportunities in the CUHK MBA programme during 2019/20. He is a Director of Hong Kong Japan Society since 2019.

Graduating with BBA degree from the Chinese University of HK, he holds a Post Graduate Diploma in E-Business from Michigan State University. He attended the Columbia Senior Executive Program in 2003. He is a Fellow of the Chartered Institute of Marketing and the Institute of Directors of the UK.



Guoliang Yu 余国良

Chairman
BayHelix

Dr. Guo-Liang Yu is the Chairman and CEO of Apollomics Inc., an innovative therapeutics company devoted to curing cancer by combining immunology and other cancer fighting methods. Before Apollomics, Dr. Yu was the Executive Chairman of Crown Bioscience Inc., a publically-listed personalized oncology platform company with ~600 employees globally. Crown Bioscience was recently acquired by JSR for \$400 million. He co-founded Epitomics Inc., an antibody biotechnology company, and served as Chairman and CEO for 10 years prior to its acquisition by Abcam for \$170 million. During his tenure at Epitomics, spun-off Apexigen Inc., an immune-oncology therapeutics company. He was also a venture partner at OrbiMed Venture LLC during 2013-2019.

Dr. Yu's success is driven by his scientific curiosity and passion for translating scientific discovery to real products. After graduating from Fudan University in Shanghai, China, he came to the United States in 1984 to pursue advanced studies. He obtained his Ph.D. from UC Berkeley, where he and Dr. Greider discovered telomerase and its mechanism in Dr. Blackburn's lab. Drs. Blackburn and Greider received Nobel Prize in 2009 for their discovery.

Dr. Yu later joined Dr. Frederick Ausubel's lab at Harvard University to pursue the question of how plants defend themselves against pathogens without an immune system, and identified the plant disease resistance gene. In 1993, when genomics was still in its infancy, Dr. Yu joined Human Genome Sciences Inc. as one of the first few senior scientists, identifying human gene targets for drug discovery. Among several important drug targets he studied was BLYS, the first successfully genomic target for the development of a lupus antibody drug Benlysta, which was approved by FDA in 2010.

In 1998, Dr. Yu was attracted to identifying plant genes with economic value in agriculture and in bio-energy. He was Senior Vice President of R&D at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors, and ultimately identified several valuable traits such as enhanced crop yield, disease resistance, and drought tolerance. Dr. Yu has co-authored 44 peer-reviewed scientific articles that have been referenced by the scientific community over 10,000 times. He is a co-inventor of more than 400 patents.

Dr. Yu currently the Chairman of Bayhelix, a leadership organization in biotech industry. Dr. Yu was the Founding President of the Chinese Biopharmaceutical Association (CBA) and serves on the boards of several professional organizations in the United States and China, including Chinese-American Bio/Pharmaceutical Society (CABS), National Foundation of Cancer Research, Ray Wu Memorial Foundation, and University of Pacific.

【NMN+靈芝】比單一配方 NMN 更抗衰老更優勝

常說「生老病死」是人生必經階段，但人為甚麼會老呢？
最簡單的解釋是人體的細胞及 DNA 隨著「年齡增長」、「氧化」、「受損」而衰老，繼而影響身體各個機能。是否沒有方法可延緩細胞衰老的速度？

NMN 是甚麼？

NMN 是 β -煙酰胺單核苷酸，與細胞輔酶 NAD⁺（諾加因子）關係密切。NAD⁺ 主宰身體多種化學作用，包括新陳代謝、DNA 修復及能量製造等等，但隨著年齡增長 NAD⁺ 水平不斷下降，這時候便需要攝取 NMN，讓 NMN 轉化成 NAD⁺，藉此增加體內 NAD⁺ 水平以達致抗衰老效果。




報告關鍵：**【NMN+靈芝】88%亞洲人細胞因抗氧化而變得年輕***

細胞衰老的一大元兇就是氧化，科學園生物科技團隊曾進行為期半年的首次針對亞洲人細胞及 DNA 研究，報告發現**【NMN+靈芝】**的配方組合產生人體細胞抗衰老協同效應，能使 88%亞洲人細胞因抗氧化而變得年輕，比單一 NMN 配方更為優勝

報告關鍵：**【NMN+靈芝】80%亞洲人細胞內的 DNA 形成保護***

DNA 的損害是人體無法避免的事，無論是體內正常代謝、日常紫外線還是幅射等等，都會破壞 DNA、令 DNA 老化。



不少文獻顯示，NMN 有助修復 DNA，而科學園的科研亦說明，加入靈芝的 NMN 配方能有效地發揮協同作用，令高達 80%的細胞能避免受到氧化劑破壞，

繼而對細胞內的 DNA 形成保護，達致修復 DNA 的作用。



NMN 內修復、靈芝外屏障 抗衰老雙管齊下

抗衰老與「自由基」及「抗氧化」等關鍵詞息息相關，要有效消除令細胞變老的自由基，便需要具備優秀抗氧化功能的物質。當中，靈芝蘊含抗氧化物靈芝醣等等，有效啟動細胞抗氧屏障、消除有害自由基，令身體回復年輕。【NMN+靈芝】組合，這組合能達致內修復、外屏障的雙重抗衰老長壽作用。

單一配方 NMN 其修復細胞的速度未必能夠抵銷細胞損毀速度，而具備極高抗氧化能力的靈芝，則可以於細胞表面形成保護層，有助抵擋及反彈外來侵襲，當靈芝配合 NMN 就能大大降低細胞及 DNA 的受損速度，達致真正的抗老逆齡效果。



- 郭致因 (Gammy Kwok)
- 草姬國際有限公司創辦人
 - 中文大學EMBA
 - 加拿大卑斯大學護理學學士
 - 加拿大自然療法醫師
 - 報章雜誌健康及管理專欄作家
 - 畫家及文字創作者

*草姬科學園生物科研團隊 2022 研究數據



Shusong Ba

Managing Director, Chief China Economist
HKEX

Professor Ba Shusong is Managing Director, Chief China Economist of Hong Kong Exchanges and Clearing Limited (HKEX), Chief Economist of the China Banking Association (CBA) and Executive Director of the HSBC Financial Research Institute at Peking University. He is also Vice President of the China Society of Macroeconomics, a member of Ministry of Commerce's Economic and Trade Policy Advisory Committee, a member of China Banking and Insurance Regulatory Commission's Expert Guidance Committee for the banking industry's implementation of the new Basel capital accord, a member of China Securities Regulatory Commission's M&A Specialists Committee, a member of China's "13th Five-Year Plan" National Development and Planning Specialists Committee, and Director-General of Peikang Chang Research Foundation of Development Economics.

Professor Ba is a fellow of experts who receive the State Council's special allowance. He was previously Deputy General Manager of the Bank of China Hangzhou Branch, Assistant General Manager of Bank of China (Hong Kong), Director-General of the Strategy and Development Committee of the Securities Association of China, and Deputy Director-General of the Financial Research Institute of the State Council's Development Research Centre. He was engaged in post-doctoral research in the China Center for Economic Research at Peking University and was a senior visiting scholar at Columbia Business School. He also served as the chief expert in the basic research field of "International Economic and Financial Structure" in Development Research Center of the State Council. Professor Ba was awarded by China's Social Science Assessment in 2017 as the Chinese scholar with the highest citation frequency in Chinese literature on economics from 2006 to 2015.

Professor Ba had participated in a large number of seminars and forums held by policy-makers in the financial fields as a financial specialist, and lectured to members of the Political Bureau of the CPC Central Committee in China as the main speaker. He had held management positions in a wide range of financial institutions including commercial banks, securities companies, public funds and trust companies. As an expert who is familiar with the actual practice of China's financial operations and policy-making process as well as well versed in financial theory research, he possesses rich practical experience and research achievements in the fields of the Basel capital accord and risk management, asset management (has published an annual report on China's asset management industry development in 11 consecutive years), banking development and bankers survey (has led the conduction and publication of the annual bankers survey reports in Chinese and English for 8 years), etc. His publications (in Chinese) include "Research on New Basel Capital Accord", "Basel II in Financial Crisis: Challenges and Improvements", "Study on Basel Capital Accord III", "Basel III and Financial Regulatory Reform", "Annual report of China Asset Management Industry Development". Professor Ba received the Global Youth Leader Award from the World Economic Forum in 2009.



Winnie Han

Senior Vice President
HKEX

Ms. Winnie Han is the Head of China Issuer Services and Senior Vice President of Global Issuer Services in HKEX. Her key focus is to lead the China team to promote HKEX as the top listing venue for Greater China companies. She has extensive coverage and works closely with potential issuers, investors, governments, associations and intermediaries. She is a familiar face on many New Economy, Advanced Technology or Healthcare Forums/Summits/Conferences promoting Hong Kong as the Go-To IPO destination.

Prior to her current role, Ms. Han had over 15 years of experiences in China A-share investment banking at UBS and Credit Suisse. Before joining HKEX, she was the Co-Head of ECM at Credit Suisse Founder Securities. She holds China A-share Sponsor Representatives Qualification and Certified Public Accountant Qualification of China (non-practicing).

Ms. Han received her Master's degree from Peking University and Bachelor's degree from Xiamen University.



Mengyang Yang 杨孟洋

Executive Director
CICC Capital

Ms. Mengyang Yang is an Executive Director and Head of Hong Kong PE Business of CICC Capital, the PE arm of China International Capital Corporation Limited ("CICC"). Ms. Yang initially joined CICC in 2015 working on investments in mid-cap PE funds in the US and Europe and co-investments. Upon re-joining CICC in 2022, she is responsible for all aspects of the business of CICC Capital in Hong Kong and leads CICC Capital's expansion into international markets.

Ms. Yang received her BA in finance and LLB from the University of International Business and Economics, and her LLM from the London School of Economics and Political Science.



Andrew Ng 伍兆威

Managing Director and Head of Healthcare
VMS Group

Andrew Ng is a Managing Director and Head of Healthcare of VMS Group and an Investment Partner of Panacea Venture. He has over 13 years of experience in the healthcare industry across Asia and the US. Andrew has established the healthcare practice of VMS Group in 2017 and led multiple growth-stage investments for VMS across the therapeutics, diagnostics, medical device and CRO/CDMO verticals. He has also served as an Investment Partner of Panacea Venture, a global healthcare venture capital firm, since 2021.

Prior to that, Andrew was responsible for the China Healthcare Equity Research at Barclays Capital based in Hong Kong. Before that, he was an investment banker covering healthcare clients across the Asia Pacific region at Barclays Capital with a focus in healthcare cross-border M&A. Andrew started his career as a management consultant at ZS Associate in the United States advising global pharma on sales & marketing strategy and operations.

Andrew has been on the board of multiple companies that carry out product development, manufacturing and sales in the biotechnology, medical equipment and CXO industries. These companies include New Horizon Health, Chime Biologics, Jade Biomedical, SyMap Medical, Yizun Biomedicine and Profusa. Andrew received an MBA from INSEAD, a M.Eng. degree and a BS degree in Operations Research & Engineering from Cornell University.



Liu Chang

CEO & Founder
ASK Health Asia

Dr. Chang LIU is the CEO and founder of ASK Health Asia. ASK Health Asia is a catalyst for health systems transformation in Asia. Through in-depth research, consultancy, platform creation, solution co-creation and resource connection, the company works closely with leading industry leaders to provide innovative solutions to jointly promote new tangible health policies and capture growth opportunities within a global emerging economy.

Prior to establishing ASK Health Asia, Dr. Liu was a Regional Director at ACCESS Health International, Inc., a global non-profit organization, overseeing the business development in both China and Singapore for over seven years. As the work developed and matured across both regions, Dr. Liu formally spun off the ACCESS Health China entity into a ASK Health Asia, to fully accelerate the company's work and impact across Asia.

TECHNOLOGY HALL | 科技廳

Bioethics and RNA Science

Wednesday, September 13 | 12:40 PM - 17:30 PM (GMT+8)

Ethics In The Biotech Industry	
12:40 - 13:30	<p>Chair: Dr. Brian Wong, Oxford Political Review*</p> <p>Panelists: Prof. Yi Rao, Capital Medical University Dr. Dong Dong, The Chinese University of Hong Kong Ms. Monin Ung, Mung Legal</p>
13:30 - 14:00	Lunch Break
RNA Medicine: Therapeutics, Vaccine and Beyond (Sponsored by Sirnaomics)	
14:00 - 14:10	<p>Embracing a New Era of RNA Medicine, Biopharma Innovation in the Greater-Bay Area Prof. Xiaochang Dai, Sirnaomics</p>
14:10 - 14:30	<p>Advancing Delivery Technology for Innovative RNAi Therapeutics, from Benchtops to Bedsides Dr. Patrick Lu Sirnaomics</p>
14:30 - 14:50	<p>Clinical Development for PNP-based and GalNAc-based RNAi Therapeutic Products Dr. Francois Lebel Sirnaomics</p>
14:50 - 15:10	<p>Unlocking the Future: Exploring mRNA's Boundless Potential in the Post-COVID Landscape Dr. Dong Shen RNA immune</p>
15:10 - 15:30	<p>Building Commercial Scale Manufacturing Facility for RNA Medicine Products, from Guangzhou to Hong Kong Dr. Edward Wang Sirnaomics</p>
15:30 - 15:50	Coffee Break
15:50 - 16:30	<p>Biopharma - Academic Partnerships Panel: Exploring the Future of RNA Investment & Collaborations Moderator: Xiao Chang Dai, PhD, Executive Director and Chief Strategy Officer, Sirnaomics</p> <p>The biopharmaceutical sector is considering RNA-based drugs as a vital component. This community thrives on strategic alliances, which allow for cross-functional sharing of knowledge, skills, and experience across different disciplines to truly advance RNA technologies to accelerate drug development to patients faster. This session is your ideal opportunity to ask your burning questions to a leading biopharma panel in pursuit of sharing their business insights on partnerships in this space.</p> <ul style="list-style-type: none">• Exploring the complexities, risk, and decision-making strategies for developing, acquiring, and advancing innovative approaches• Where are the gaps in using RNA approaches, that can be filled by the biotechnology sector?• Developing successful expertise in house vs asset acquisition partnering strategies <p>Panelists: Min Wu, PhD Chief Business Officer at Therorna Da Liu, Managing Director, CR-CP Life Science Fund Christopher Kennedy, CEO, EDIRNA Nancy Man, PhD, MD, Chair Professor, Hong Kong University</p>
16:30 - 16:45	<p>Key considerations for development and commercialization of mRNA vaccine and therapeutics Yuling Li, PhD, President, Zhejiang Innoforce Pharmaceuticals Co., Ltd.</p>
16:45 - 17:00	<p>Focusing Oligonucleotide Product Manufacturing, Providing High-Quality Drug Product for RNA Medicine. Michael Zhang, MBA, Vice President, Guangzhou Ribo Biotechnology</p>
17:00 - 17:20	<p>Lessons Learned in Developing and Scaling Novel Platforms for RNA Medicine Products Richard Welch, PhD, Vice President, CMC, Sirnaomics</p>
17:20 - 17:30	Patrick Lu, PhD Closing Remarks + Photoshoot

Sponsored by



Dong Dong 董咚

Assistant Professor

JC School of Public Health and Primary Care, The Chinese University of Hong Kong

Dr. Dong Dong joined the JC School of Public Health and Primary Care as a Research Assistant Professor in 2018. She obtained her doctoral degree in Mass Communication (with a minor in Epidemiology) from the University of Minnesota, Twin Cities. Most of Dr. Dong's research are cross-disciplinary in nature and focus on issues not only related to health communication and medical sociology but also to health equity and social justice. She has been the Principle Investigator of several extramural research grants, including the Hong Kong RGC-GRF on the use of prenatal genetic testing technologies in mainland China. She is also the co-Investigator of several research grants from Hong Kong and mainland China on issues related to community health, health inequity, and healthcare services.

In addition, Dr. Dong is collaborating with several national patient organizations in China to investigate, trace and record the medical, social, and economic status of the Chinese people affected by different types of rare diseases. She is currently leading a research lab in the Shenzhen Research Institute of CUHK on developing a patient-centered real-world database for studying people with rare diseases in China. She has published more than a dozen white paper reports on the topic and served as a board member for three national rare disease patient organizations.



Monin Ung 黃夢瑩

Legal Advisor

Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance

Ms. Ung serves as a director at Adlux AI Group Limited operated out of Germany since November 2019. Ms. Ung is the legal adviser to the Greater Bay Area Biotech Alliance since June 2020 and she founded the Oxford Futurists group for futuristic forum discussions. Ms. Ung founded Mung7Art in January 2021, which is an art collective of digital artists across the world. Ms. Ung established the boutique legal practice of MUNG (黃夢瑩律師事務所) in July 2018 and has been serving as the managing partner since then. Prior to that, Ms. Ung held several positions in U.K. and U.S. international law firms where she advised clients on corporate finance and private equity transactions and intellectual property disputes. Ms. Ung received a bachelor's degree of law (LL.B.) from Brunel University in the U.K. in July 1991, a master's degree of law (LL.M.) in Chinese and Comparative Law from the City University of Hong Kong in November 2001, and has been on the executive master's degree of business administration (EMBA) from Said Business School at the University of Oxford since January 2017. Ms. Ung became an advocate and solicitor in Singapore in May 1994, and a solicitor in Hong Kong in May 1997. She is also a recipient of the Hong Kong Chief Executive's Commendation for Community Service Award in July 2015.



Xiaochang Dai 戴晓畅

**Executive Director / Scientific and Strategic Director
Sirnaomics**

Dr. Dai Xiaochang has over 20 years of experience in biotech technology. Prior to joining Sirnaomics, Dr. Dai served as the chairman of Yunnan Walvax Biopharmaceutical Co., Ltd., the predecessor of Walvax Biotechnology Co., Ltd. a company listed on Shenzhen Stock Exchange, the managing director of Kunming Baker Norton Pharmaceutical Co., Ltd. in 2005, and the president of Kunyao Group Co., Ltd. a company listed on Shanghai Stock Exchange.

Dr. Dai participates in the formulation of the general corporate business plans, strategies and major decisions of Sirnaomics through the Board. Dr. Dai currently serves as a professor at the School of Chemical Science and Engineering, Yunnan University since 2000, the executive director of Value Measure Investments Limited since January 2011 and the executive director of Trinity Power Limited since March 2012, respectively. Dr. Dai also serves as a director of Shenzhen Yunda Technology Industry Co., Ltd. since August 2001.

Dr. Dai obtained a master's degree in biochemistry in Shanghai Institute of Biochemistry, Chinese Academy of Sciences in the PRC. During this period, he and his team developed the sixth type of plant hormone, "Yunda-120". They later became a widely used plant growth regulator. Dr. Dai finished his doctoral degree in chemistry from The Scripps Research Institute in San Diego, California, U.S., and he also conducted postdoctoral research in the laboratory of John N. Ablelson, Division of Biology and Biological Engineering, California Institute of Technology in the U.S. from November 1998 to December 1999. At that time, his main research project was the development of nucleases for biotherapeutic use using in vitro evolutionary techniques.



Patrick Lu 陸陽

**Founder, President and CEO
Sirnaomics**

Dr. Lu started his biopharmaceutical industry career in 1993 as a lab head in Novartis and was the co-founder and Executive VP of Intradigm Corporation (2001-2006). Patrick has authored more than 50 scientific papers, review articles and book chapters, and is an inventor for more than 50 issued and pending patents. He has been an invited speaker in many international conferences throughout the world and received a number of Government grants. Under his leadership, Sirnaomics has raised more than US\$170 million dollars and has developed a series of "first-in-class" siRNA therapeutic candidates at different phases of clinical studies, for treatment of cancer and fibrosis diseases, in both USA and China.



Francois Lebel

**Senior Vice President for Preclinical and Clinical Development
Sirnaomics**

Dr. Lebel is a strategic leader with broad drug development experience including immunooncology and nucleic acid therapeutics. Throughout his 30-year biopharma career at companies such as GSK, Pfizer, Baxter Healthcare, MedImmune, and Chiron Corporation, Dr. Lebel has designed and managed international research and development programs to successfully achieve multiple product marketing approvals. His recent senior leadership roles include Executive Vice President for Research & Development and Chief Medical Officer at Spectrum Pharmaceuticals (a Nasdaq-listed company; stock code: SPPI), where he was responsible for preclinical and clinical development, regulatory affairs and pharmacovigilance/drug safety, and successfully secured a novel drug marketing authorization at the U.S. Food and Drug Administration (FDA) in 2022. After joining Sirnaomics as Senior Vice President for preclinical and clinical development, Dr. Lebel will take a leading role in the Group's late-stage product development of innovative RNAi drug candidates.



Dong Shen

**Vice President and Professor
RNAimmune**

Dr. Shen graduated with PhD degree from Johns Hopkins University School of Medicine and MD degree from Shanghai Jiao Tong University School of Medicine. Dr. Shen has extensive drug development experience in AstraZeneca and Johnson and Johnson, having led projects across multiple therapeutic areas with high unmet medical need. He has held leadership across early and late programs in the areas of infectious disease, oncology and rare disease. Dr. Shen received numerous awards in the past. He was the recipient of Johnson & Johnson leadership award in 2018 and innovation award in 2017. All his manuscripts have been published at the most influential journals, such as Science and Nature. The total number of his publication citations is over 16,400.



Edward Wang 王永祥

**Chief Production Officer
Sirnaomics**

Dr. Wang is an internationally recognized expert in large-to-commercial scale manufacturing of biopharmaceutical and vaccine products, with specialization in aseptic processes and GMP compliance. He has more than 25 years of experience in the biopharmaceutical industry and at NGOs, including serving as the vice president of technical operations at Wuxi Biological Base of WuXi AppTec Co., Ltd.; the director of vaccine production at Newlink Genetics Inc.; the deputy director of engineering at a non-profit organization affiliated with the Bill & Melinda Gates Foundation; the technology consultant of Parexel International at Ben Venue Laboratory of Boehringer Ingelheim; and the senior scientist and manager in the Biopharmaceutical development program at the U.S. National Cancer Institute. Dr. Wang received his bachelor's degree of biophysics at the University of Science and Technology of China, a master's degree of biochemistry at the Tokyo Institute of Technology in Japan, and a doctoral degree at the Helsinki University of Technology in Finland.



Min Wu

**Chief Business Officer
Theron Inc.**

Min has more than 15 years of pharmaceutical and biotech R&D and business development experience. Currently served as CBO of Theron Inc. Before joining Theron, Min worked as the Managing Director of Fosun Health Fund. Before that, Min served as Executive Director of the Asia Pacific Innovation Hub of MSD, responsible for R&D business development in various therapeutic areas covering Greater China region and South Korea. Prior to MSD, she was the Head of External R&D and Licensing for Amgen Asia R&D Center, responsible for the center's scientific outreach and alliance management of the external strategic partnerships. She was also in charge of Search & Evaluation for Amgen's Global Business Development for the JPAC region. Min worked in different functions at Roche including Partnering, Alliance and Portfolio Management. Min obtained her Ph.D. in computational biology and chemistry from New York University, conducted post-doctoral research at Pfizer La Jolla site and subsequently worked as Principle Scientist at GlaxoSmithKline in North Carolina, US. Min has an MBA from University of Manchester, UK.



Da Liu 柳達

**Managing Director
CR CP Life Science Fund**

Mr. Liu is now the Managing Director of the CR CP Life Science Fund, whose shareholders, CR Group and CP Group are on the Fortune Global 500 List. Before that, Mr. Liu was the Business Director of the Strategic Management Department at CR Group, responsible for strategic research and project investment in life science and technology; and as Senior Director of China Resources Pharmaceutical Group Co., Ltd. (HK: 03320), responsible for business development and international cooperation. He has also served as the Senior Director of China Resources Pharmaceutical Business Group, the General Manager of China Resources Pharmaceutical Airport (Beijing) International Trading Co., Ltd., the Deputy General Manager of Beijing Pharmaceutical Co., Ltd., and the COO of Zhoulin Bio-spectrum Technology Co., Ltd. Prior to 2004, Mr. Liu was a pharmacy manager at CVS Group in the United States, and worked at the New York Healthcare Group as a clinical pharmacist.



Nancy Man 萬鈞

**Chair Professor of Transplant Oncology and Immunology
The University of Hong Kong, LKS Faculty of Medicine**



Dr. Nancy K MAN main research focus is in the area of liver graft injury and cancer recurrence after transplantation utilizing an integrated basic, clinical and translational approach. She has developed a series of novel animal models to mimic liver graft injury and cancer recurrence. She is also the first to establish a rat orthotopic liver transplantation model using small-for-size grafts in Hong Kong. These models have been extensively introduced into the investigation of liver transplantation. She is the first to report the significance of small-for-size liver graft injury on tumor recurrence after transplantation in the world and further to explore the molecular mechanisms of inflammatory response in the acute phase and tumour invasiveness in the late phase.



商務印書館(香港)
THE COMMERCIAL PRESS (HK)

獨具慧眼迎商機 創新出版知趨勢

BOOTH NO. 3D-C34, 3D-D33





Christopher Kennedy

CEO, EDIRNA

Over 20 years of executive, commercial, and operational leadership in the life sciences industry. Accelerating innovation and growth at all stages of company development.

Christopher W. Kennedy is an award-winning healthcare leader. He has spent the last two decades in executive leadership roles within the Healthcare Provider, Biotechnology, and Medical Device sectors. His efforts in making Patient Experience a measurable outcome have been featured by The Beryl Institute, The Wharton School, a PBS TV Special, and a 2019 Ted Talk presentation. He actively serves on multiple industry advisory boards including MOBIO, URAC, NASP, and The Kauffman Foundation's Skilled KC initiative.



Yuling Li 李玉玲

President

Zhejiang Innoforce Pharmaceuticals Co., Ltd.

Dr. Yuling Li is the co-founder and President of Innoforce Pharmaceuticals, a company established in 2018 at Hangzhou, China with the focus of building CDMO capabilities for innovative drug development including nucleic acid products (plasmid DNA and RNA), viral vector and cell therapy and monoclonal antibody products. Prior to Innoforce, Dr. Li was the Sr. Vice President of Process Development and Manufacturing of Apollomics (Foster City, CA and Hangzhou), the R&D Fellow/Director in BioPharmaceutical Development at MedImmune/AstraZeneca (Gaithersburg, MD), the Senior Director in BioPharmaceutical Development at Human Genome Sciences Inc. (now part of GSK, Rockville, MD) and an Associate Scientist at Hoffmann-La Roche Inc. in Nutley, New Jersey. In the past 30 years, Dr. Li led CMC activities for 3 BLA submissions and contributed to 9 approved products plus 30+ biopharmaceuticals through various clinical stages of CMC development.

During the course of her career, Dr. Li published 40+ peer-reviewed articles and book chapters and is the inventor for five issued patents. In 2014, Dr. Li received the Rising Star Award from the Healthcare Businesswomen Association. Dr. Li served as the President (2007-2008), Board of Directors, member of the Advisory Board for the Chinese Biopharmaceutical Association-USA (CBA, www.CBA-USA.org), a non-profit professional organization. Dr. Li also co-founded the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA) in 2008. She is a BayHelix member.



Michael Zhang

Vice President
Guangzhou Ribo Biotechnology

Michael Zhang is the Vice President of Project Development at Guangzhou RiboBio, where he leads project management of the CDMO sector for global clients. He also heads the operations team and oversees Ribobio's industry collaboration portfolios. Michael has a background in management and business and is a graduate of Columbia University. RiboBio is a forerunner in oligonucleotide services and products in Asia, providing a one-stop solution for clients seeking oligonucleotide manufacturing at all stages.



Richard Welch

Vice President
CMC, Sirnaomics

Richard Welch is an experienced professional with a career spanning over 26 years. Throughout his journey, he has worked in various roles and industries, showcasing his adaptability and breadth of expertise. Currently serving as the Vice President CMC at Sirnaomics, Inc., Richard has been dedicated to this position for 730 days. Prior to his current role, he held key leadership positions at Emergent BioSolutions, including Vice President Development Services, CDMO Business Unit, Vice President Process and Analytical Development, and Senior Director Process and Analytical Development, where he contributed significantly to the company's growth and success. Richard's experience also extends to other notable companies, such as Lonza Inc., Chesapeake PERL, Claragen, and North American Vaccine (now part of Baxter). He holds a Doctor of Philosophy (Ph.D.) from Rice University and a Bachelor of Science (BS) from the University of Illinois at Urbana-Champaign. With his extensive background in CMC, process development, analytical development, and manufacturing, Richard Welch is a valuable candidate for roles in the biotechnology and pharmaceutical industries.

LOCI'S SQUARE | 基因位點廣場

Regenerative Medicine & Sponsored Events

Wednesday, September 13 | 12:40 PM - 17:00 PM (GMT+8)

Hong Kong's Technology Innovation Transformation (Sponsored By Shanghai Healthcare Capital)

12:40 - 13:30

Moderator: Mr. Qiushan Guo, Shanghai Healthcare Capital*

Panelists:

Mr. Min Zuo, Shanghai Healthcare Capital*

Dr. Pengcheng Zhu, ATLATL*

Prof. Yuk Ming Lo, Chinese University of Hong Kong*

Prof. Yuk Lam Lo, HKBMIA*

13:30 - 14:00

Lunch Break

Reprogramming for Regenerative Medicine

14:00 - 15:30

Chair: Prof. Kathryn Cheah

Panelists:

Prof. Pengtao Liu, The University of Hong Kong

From basic stem cell biology to potential stem cell therapy

Prof. Ting Xie, Hong Kong University of Science and Technology

原位神经再生疗法引领神经制药新赛道

Prof. Gong Cheng, Jinan University

Progenitors and lineage directed in vitro differentiation of nucleus pulposus cells relevant for intervertebral disc degeneration

Prof. Kathryn Cheah, The University of Hong Kong School of Biomedical Sciences

Dr. Hongmei Li, Beijing University of Chinese Medicine

16:00 - 17:00

Sponsored Event
Asian Life sciences and Healthcare Industry Financial Forum
(by invitation only, Beijing ITAI Technology)

**No biography or information was provided before September 01, 2023.*

Tr@nsform[®]

健康在乎你取態

NMN
Water

Alkaline
Water



逆齡抗衰老



修復受損DNA



激活長壽蛋白

全球首創
新一代提升
NAD+ 飲料



pH9

軟水

植物
礦物質

BOOTH NO. 3D-D26

Booth No : 3D-D26

Whatsapp
+852 6588 8183



全新網站
歡迎訂購





Kathryn Cheah 謝賞恩

**Chair Professor, Department of Biochemistry
The University of Hong Kong**

Prof. Kathryn Cheah is Chair Professor of Biochemistry at HKU and an internationally renowned expert on understanding gene regulation and function and how mutations cause disease, with an emphasis on the skeletal system and the inner ear. She has contributed insights into the regulation and function of genes in vivo and the molecular pathogenesis of disease by generating transgenic mice and mouse models and by studying human degenerative skeletal disorders especially degenerative intervertebral disk disease (DDD). The driving motivation of her research is the realisation that, with an ageing population worldwide, genomic and regenerative medicine will play critical roles in helping to preserve healthy growth and quality of life. She uses human and mouse embryonic stem cells and genetically modified mice as models to study development and disease and develop therapeutic approaches for disorders of cartilage (e.g. osteoarthritis) and low bone mass (e.g. osteoporosis) and intervertebral disc degeneration.

In HKU she has served as Jimmy and Emily Tang Professor in Molecular Genetics, Chair Professor of Biochemistry, School of Biomedical Sciences, The University of Hong Kong. She was awarded a Croucher Foundation Senior Fellowship (2000) and is an elected Fellow of the global academy for the advancement of science in developing countries, The World Academy of Sciences (TWAS). In 2021 she was elected as Member of the Hong Kong Academy of Sciences. She was awarded the British Society for Matrix Biology Medal Lecture 2022 for her contributions to matrix biology.



Xie Ting 解亭

**Head and Chair Professor
Division of Life Science, The Hong Kong University of Science and Technology**

Prof. Ting Xie is Kerry Holdings Professor of Science, Chair Professor, and the head of the Division of Life Science at Hong Kong University of Science and Technology. Before moving to Hong Kong, he was an investigator at the Stowers Institute for Medical Research and a professor at the University of Kansas Medical Center. He obtained his Ph.D. in Molecular Biology and Biochemistry from Rutgers University and did his postdoctoral training at Howard Hughes Medical Institute/Carnegie Institution of Science. His main research areas include stem cell biology and eye degenerative diseases. He is one of the leaders and pioneers in studying stem cell niches. Prof. Xie has published over 70 articles in high-profile journals, including Science, Nature, and Cell. He has been serving on the scientific advisory board of the Glaucoma Foundation and the Y-LOT Foundation and on the editorial board of Cell Research, Development, and ten other scientific journals.



Gong Chen 陈功

Director

Brain Repair Center, Guangdong-Hong Kong-Macau Institute of CNS Regeneration (GHMICR) of Jinan University

Professor Chen Gong is a nationally appointed expert and Director of GHMICR at Jinan University. He graduated from Fudan University and has a PhD in Neurobiology from Shanghai Institute of Physiology, Chinese Academy of Sciences. He is a postdoctoral fellow at Yale University and Stanford University. He was a tenured professor and Endowed Chair Professor at Pennsylvania State University. Dr. Gong Chen's team reported the first landmark work of efficiently converting endogenous astrocytes into functional neurons in situ with the neurotranscription factor NeuroD1, which was named the best paper of the year in 2014 by the journal Cell Stem Cell and opened up a new neuroregenerative therapeutic approach for brain repair.

Prof. Chen Gong is the scientific founder of NeuExcell, a company dedicated to the use of neuroregenerative therapies for the treatment of neurological injuries and degenerative diseases. NeuExcell was selected as one of the top 5 promising startups in Asia by GEN, a leading biotech magazine.



Hongmei Li

Associate Researcher

Beijing University of Chinese Medicine

Li Hongmei, associate researcher at Beijing University of Chinese Medicine and a joint doctorate trained by Yale University in the United States. She is committed to the intersection of traditional Chinese medicine and regenerative medicine under the integration model of clinical scientific research. In 2019, the "Young Talent Promotion Project" of the China Association of Traditional Chinese Medicine was selected as the third batch of young truth-seeking scholars of traditional Chinese medicine. They are members of the excellent talent pool cell and youth editorial board of the "Chinese Journal of Traditional Chinese Medicine". She concurrently serves as a youth member of the Cardiovascular Disease Branch of the China Association of Traditional Chinese Medicine, a member of the Science and Engineering Technology Standards Technical Committee, a member of the Research Methods Professional Group of the Cardiovascular Disease Clinical Committee, and a member of the Aromatherapy Group of the Cardiovascular Drug Research Professional Committee of the China Association of Traditional Chinese Medicine. Hosted 6 scientific research projects of various types including the National Natural Science Foundation of China, won 1 second prize of the Natural Science Award of the China Association of Traditional Chinese Medicine, and published more than 30 academic papers for the first project/author correspondence in STTT, MedComm and other publications, and was authorized to invent. 1 patent, co-edited 2 books.



香港中文大學
The Chinese University of Hong Kong

ABOUT ORKTS 研究及知識轉移服務處



研究及知識轉移服務處
Office of Research and
Knowledge Transfer Services

中大研轉處為學人提供多方面支援，包括提供研究資金、產研合作、研究合約、知識產權的開發與授權、倫理政策、知識轉移等各方面的支援，以及推動創新創業活動。研轉處希望匯聚豐碩學研成果，鞏固中大創新創業圈的獨特優勢，將更多「知識解鎖」，惠及各個社群。

The Office of Research and Knowledge Transfer Services (ORKTS) supports researchers with research grants, industry-university collaborations, research contracts, IP development and licensing, research ethics policies and other knowledge transfer services, with a view to "unlocking" knowledge for promoting CUHK's research excellence and innovation, and their translation into social impacts and benefits.

ORKTS provides one-stop services! 研轉處提供一站式服務



Co-Working Space
共創空間



Mentorship & Incubation Programs
指導及孵化計劃



Funding & Investment Opportunities
資助及投資機會



Marketing & Publicity Channels
宣傳及推廣頻道



IP & Legal Consultation Services
知識產權諮詢服務



Workshops, Seminars & Talks
工作坊、研討會和講座



Event Venue & Facilities
活動場地及配套設施



Check out
ORKTS Website
查看研轉處網站